|
Jun 17
|
BioRestorative Announces Share Repurchase Program
|
|
Jun 13
|
BioRestorative Reports Compelling Preliminary Data for FDA-Fast-Tracked BRTX-100 – an Autologous Stem Cell Therapy to Treat Chronic Lumbar Disc Disease
|
|
May 15
|
Q1 2025 BioRestorative Therapies Inc Earnings Call
|
|
May 15
|
BioRestorative Therapies Inc (BRTX) Q1 2025 Earnings Call Highlights: Navigating Challenges ...
|
|
May 14
|
Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 14
|
BioRestorative Therapies Reports First Quarter 2025 Financial Results and Provides Business Update
|
|
May 13
|
Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data
|
|
May 8
|
BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025
|
|
May 7
|
BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025
|
|
Apr 15
|
BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities
|
|
Apr 10
|
BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States
|
|
Feb 20
|
BioRestorative Receives FDA Fast Track Designation for BRTX-100 Chronic Lumbar Disc Disease Program
|